Indication
BRCA2 gene mutation
3 clinical trials
3 products
2 drugs
Clinical trial
A Phase 2 Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation CarriersStatus: Active (not recruiting), Estimated PCD: 2021-05-01
Product
ABT-888Drug
temozolomideClinical trial
A Phase Ib Study of the Oral PARP Inhibitor Niraparib With the Intravenous PI3K Inhibitor Copanlisib for Recurrent Endometrial and Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerStatus: Active (not recruiting), Estimated PCD: 2026-12-31
Product
CopanlisibDrug
AtezolizumabClinical trial
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)Status: Active (not recruiting), Estimated PCD: 2022-01-01
Product
Rucaparib